Alkem Laboratories Limited (BOM:539523)

Market Cap	645.95B +8.9%
Revenue (ttm)	142.53B +11.7%
Net Income	23.71B +10.1%
EPS	198.31 +10.1%
Shares Out	n/a
PE Ratio	27.24
Forward PE	27.37
Dividend	51.00 (0.94%)
Ex-Dividend Date	Feb 20, 2026

Volume	13,159
Average Volume	2,783
Open	5,750.25
Previous Close	5,858.30
Day's Range	5,332.45 - 5,855.00
52-Week Range	4,498.90 - 5,933.00
Beta	n/a
RSI	36.43
Earnings Date	Feb 13, 2026

About Alkem Laboratories

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastroenterology, pain management, iron deficiency, diabetology, central nervous system, anti-osteoporosis, gynecology, respiratory, ophthalmology, r...

• Industry: Pharmaceutical Preparations
• Founded: 1973
• Employees: 18,785
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 539523

Financial Performance

In fiscal year 2025, Alkem Laboratories's revenue was 129.65 billion, an increase of 2.34% compared to the previous year's 126.68 billion. Earnings were 21.65 billion, an increase of 20.59%.